Abstract 5973
Background
Chemotherapy is the cornerstone of the treatment of patients with non‐metastatic breast cancer; however, its toxicity may be limiting. It has been reported that some degree of toxicity is present in 98% of patients. To date, no predictors of this toxicity have been identified. Bioimpedance and Phase Angle (PA) are non‐invasive procedures to evaluate nutritional status. The aim of this study was to associate the PA with chemotherapy toxicity during (neo)adjuvant (neoCT) treatment of breast cancer.
Methods
172 patients were prospectively evaluated, 31 were excluded because they had metastatic disease or had received endocrine therapy. Only chemotherapy candidates were enrolled, patient selection criteria were PS 0‐1, adequate liver, hematologic and renal function tests. The chemotherapy regimen consisted in AC‐T at standard doses and schedules +/‐ cisplatin in triple-negative tumors. Toxicity was evaluated per NCI CTC v4.0. In all patients bioimpedance by SECA mBCA 514 and Inbody 720 were registered. Statistical analysis was done with SPSS v20.0.
Results
141 were analyzed, median age was 50 years old, 53.2% of them received neoCT and 46.8% adjuvant CT. Regarding comorbid status, 10.6% had diabetes, 14.0% had hypertension, most of the patients were obese or over weight, median BMI was 27.7kg/m2 (13.79‐39.84 kg/m2), median waist circumference was 97.30cm (72‐135 kg/m2), overall metabolic syndrome per ATPIII criteria was found in 34.1% of all patients. 54.3% were diagnosed in early stage (I‐IIb), 24.2% were HER2‐positive, 46.8% were HR‐positive and 29.1% were triple negative. Any grade of toxicity was present in 98.6%, 9.9% required hospitalization and in 2.1% toxicity led to death, most common side effects were gastrointestinal 85.8%, fatigue 70.9%, peripheral neuropathy 50.4% and hematologic 48.9%. PA average was 4.8° (2.8‐6.26°). We found a correlation between PA and any grade of toxicity (p = 0.022). Patients with low PA had more G3-5 toxicity (p = 0.045). and more peripheral neuropathy (p = 0.045).
Conclusions
PA helps us to assess nutritional status and it seems to be useful as a toxicity predictor. However, external validation is necessary to confirm this benefit.
Clinical trial identification
Legal entity responsible for the study
Maria Tereza Nieto Coronel.
Funding
Has not received any funding.
Editorial Acknowledgement
Any
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4942 - Analytical validation of OncoMasTR, a multigene test for predicting risk of distant recurrence in hormone receptor-positive early stage breast cancer
Presenter: Tony Loughman
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5641 - Comparing the prognosis of favourable-histology breast cancers between younger women of less than 45 years of age at diagnosis with their older counterparts.
Presenter: Guek Eng Lee
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4448 - TNBC universe: a monocentric retrospective analyses of TILs and AR as prognostic markers
Presenter: Agnese Losurdo
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4755 - Genomic spectrum of Asian breast cancer based on targeted next-generation sequencing in 150 consecutive primary breast cancer
Presenter: Chihwan Cha
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2741 - The Impact of the 21 Gene Recurrence Score (RS) on Chemotherapy (CHemoRx) Prescribing in Hormone Receptor (HR) Positive, Lymph Node Positive (LN+) Early-Stage Breast Cancer (BC) in Ireland: A National, Multi-centre, Prospective Study (CTRIAL-IE 15-34)
Presenter: Anees Hassan
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3356 - Lymphocyte-predominant breast cancer has a significant lower mean of absolute neutrophil counts compared to non-lymphocyte-predominant breast cancer: Analyses with 576 cases
Presenter: Da Young Lee
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4020 - Genetic Alterations of Early-Stage Breast Cancers by next-generation sequencing (NGS)
Presenter: Yan Xu
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4924 - Oncotype Dx results in patients _40 years, Does age matters?: new insights
Presenter: Fernando Namuche
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2646 - Impact of BRCA status on outcomes and survival in high-risk early breast cancers
Presenter: Elodie Klajer
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4516 - Early breast cancer classified as intermediate risk by the Prosigna assay: Characteristics and treatment strategy
Presenter: Nawale Hajjaji
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract